AGIO Quote, Financials, Valuation and Earnings

Blueprint Medicines has a net margin of -899.56% compared to Agios Pharmaceuticals's net margin of -34.13%. Agios Pharmaceuticals's return on equity of 62.58% beat Blueprint Medicines's return on equity of -24.43%.

Agios Pharmaceuticals has a consensus price target of $53.60, signalling upside risk potential of 94.78%. On the other hand Blueprint Medicines has an analysts' consensus of $124.90 which suggests that it could grow by 51.34%. Given that Agios Pharmaceuticals has higher upside potential than Blueprint Medicines, analysts believe Agios Pharmaceuticals is more attractive than Blueprint Medicines.

Agios Pharmaceuticals has a beta of 0.831, which suggesting that the stock is 16.932% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.37%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $10.7M, which are smaller than Blueprint Medicines quarterly revenues of $146.4M. Agios Pharmaceuticals's net income of -$96.5M is lower than Blueprint Medicines's net income of -$50M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.43x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 43.44x versus 10.29x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -899.56% compared to Agios Pharmaceuticals's net margin of 1.4%. Agios Pharmaceuticals's return on equity of 62.58% beat Bruker's return on equity of 6.78%.

Agios Pharmaceuticals has a consensus price target of $53.60, signalling upside risk potential of 94.78%. On the other hand Bruker has an analysts' consensus of $62.05 which suggests that it could grow by 55.25%. Given that Agios Pharmaceuticals has higher upside potential than Bruker, analysts believe Agios Pharmaceuticals is more attractive than Bruker.

Agios Pharmaceuticals has a beta of 0.831, which suggesting that the stock is 16.932% less volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.5% to investors and pays a quarterly dividend of $0.05 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agios Pharmaceuticals quarterly revenues are $10.7M, which are smaller than Bruker quarterly revenues of $979.6M. Agios Pharmaceuticals's net income of -$96.5M is lower than Bruker's net income of $13.7M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.43x while Bruker's PE ratio is 52.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 43.44x versus 1.77x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics has a net margin of -899.56% compared to Agios Pharmaceuticals's net margin of -6391.57%. Agios Pharmaceuticals's return on equity of 62.58% beat Janux Therapeutics's return on equity of -11.37%.

Agios Pharmaceuticals has a consensus price target of $53.60, signalling upside risk potential of 94.78%. On the other hand Janux Therapeutics has an analysts' consensus of $85.33 which suggests that it could grow by 194.76%. Given that Janux Therapeutics has higher upside potential than Agios Pharmaceuticals, analysts believe Janux Therapeutics is more attractive than Agios Pharmaceuticals.

Agios Pharmaceuticals has a beta of 0.831, which suggesting that the stock is 16.932% less volatile than S&P 500. In comparison Janux Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Janux Therapeutics pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $10.7M, which are larger than Janux Therapeutics quarterly revenues of $439K. Agios Pharmaceuticals's net income of -$96.5M is lower than Janux Therapeutics's net income of -$20.2M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.43x while Janux Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 43.44x versus 119.24x for Janux Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -899.56% compared to Agios Pharmaceuticals's net margin of -2357.27%. Agios Pharmaceuticals's return on equity of 62.58% beat Palatin Technologies's return on equity of --.

Agios Pharmaceuticals has a consensus price target of $53.60, signalling upside risk potential of 94.78%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Agios Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Agios Pharmaceuticals.

Agios Pharmaceuticals has a beta of 0.831, which suggesting that the stock is 16.932% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $10.7M, which are larger than Palatin Technologies quarterly revenues of $350K. Agios Pharmaceuticals's net income of -$96.5M is lower than Palatin Technologies's net income of -$2.4M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.43x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 43.44x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.